Ospemifene May Not Treat Vulvar Atrophy: A Report of Two Cases

INTRODUCTION: Ospemifene (Osphena, Shionogi Inc, Florham, NJ, USA) is an estrogen agonist and antagonist approved by the U.S. Federal Drug Administration for the treatment of “moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.” Although published, peer-reviewe...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldstein, Andrew T., King, Michelle A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5005291/
https://www.ncbi.nlm.nih.gov/pubmed/27373143
http://dx.doi.org/10.1016/j.esxm.2016.05.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5005291/
https://www.ncbi.nlm.nih.gov/pubmed/27373143
http://dx.doi.org/10.1016/j.esxm.2016.05.002

Ejemplares similares